Company Overview
CeriBell, Inc. operates as a medical technology company within the United States, focusing on the development and commercialization of the Ceribell System. This novel point-of-care EEG platform is specifically engineered to address critical unmet needs for patients in acute care settings, while the company also provides disposable, flexible headbands. The firm functions within the broader Healthcare sector, specifically targeting the Medical Devices industry, which encompasses the creation of tools essential for diagnosis and treatment in clinical environments. The company currently maintains a market capitalization of $668.88M and reports trailing twelve-month revenue of $89.06M, supported by an employee base of 327 individuals. These valuation and revenue figures indicate that CeriBell has established a significant footprint as a mid-cap entity in the specialized medical device market, positioning it as a notable player despite its current financial challenges.
Financial Health
The company reported a trailing twelve-month revenue of $89.06M, yet posted a net income of -$53,412,000 and an EBITDA of -$57,061,000 for the same period. The substantial gap between the $89.06M in revenue and the -$53,412,000 net income reveals a cost structure characterized by high operating expenses that are currently exceeding gross profitability. CeriBell holds $159.26M in cash reserves against $22.28M in total debt, resulting in a debt-to-equity ratio of 14.34. This balance sheet composition suggests a leveraged position where significant cash on hand is utilized to service or offset the equity-weighted debt burden. The company maintains a current ratio of 9.73, which indicates robust short-term liquidity and an ability to cover obligations well beyond immediate requirements. However, the return on equity stands at -30.8% and the return on assets is -17.3%, metrics that reveal that management effectiveness in generating profit from shareholder equity and total assets is currently negative. Furthermore, the generation of free cash flow stands at -$23,596,500, indicating that operating cash outflows exceed cash inflows from operations, constraining immediate financial flexibility for capital allocation.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the absence of net income, while the forward P/E is recorded at -17.67. The disparity between these metrics and the negative forward multiple implies that the market prices in future earnings recovery or that current negative earnings trajectories are not yet reflected in standard trailing valuation multiples. The price-to-book ratio is 4.29, indicating that the market values the company at more than four times its net asset value, suggesting a premium assigned to its intellectual property and growth potential. Additionally, the price-to-sales ratio is 7.51, and the EV/EBITDA stands at -9.32; these alternative valuation metrics suggest that investors are prioritizing revenue growth and market share over current profitability when assessing the stock's worth. The 52-week high is $24.33 and the 52-week low is $10.01, placing the current trading range within a volatile band where the stock has demonstrated significant price elasticity over the past year. The beta is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market based on historical standard deviation data provided in the available facts.
Growth & Income
Revenue growth year-over-year is reported at 33.7%, while earnings growth is N/A due to negative net income figures. The absence of positive earnings growth while revenue expands at a rapid pace implies that the company is in an investment-heavy phase where top-line expansion is occurring before bottom-line profitability is achieved. As a non-dividend payer, CeriBell does not distribute a dividend yield or a payout ratio, instead choosing to reinvest all available earnings into research, development, and operational scaling rather than returning capital to shareholders. This strategy aligns with the profile of a growth-stage medical device firm where capital retention is essential for funding the Ceribell System development and market penetration. The overall growth and income profile reflects a high-revenue-growth strategy devoid of current income generation, relying entirely on future operational leverage to convert the current revenue stream into profitable earnings.